Cardioprotection thread, page-906

I don't know about the shareprice, but if CPACS is definitively confirmed in a broad spectrum of cancers, the value of Bisantrene increases by an order of magnitude.

The mechanism of cardiotoxicity shared by all drugs used in preclinical and human trials with Bisantrene is ROS production, the primary driver of cardiotoxicity for Doxorubicin.

Confirmation of cardioprotection in combination with Doxorubicin validates all in-human clinical trials where Bisantrene was used in combination with less cardiotoxic regimens.

Dexrazoxanes mechanisms of action is regulating iron homeostasis and topo2 inhibition, which appears to be different to Bisantrene, as these pathways are not upregulated by most drugs and particularly proteasome inhibitors, the only other definitive drug used in vitro with Bisantrene.

If regulating iron homeostasis is enough to provide meaningful cardioprotection, then I have a very high level of confidence for strong cardioprotection in humans.

All the available evidence suggests Bisantrene is broad acting and extremely competitive with other regimens when it is used correctly for its mechanisms of action. History suggests that if Bisantrene is able to meaningfully decrease ROS production to preserve heart health in humans, then it also suggests that this doesn't disrupt the ability for Bisantrene to synergise with therapy.

For every 1 patient that demonstrates CPACS in combination with Dox, it adds significant weight to the running hypothesis that Bisantrene is a first in class CPACS drug.

The ultimate CPACS drug is one that is broad acting, synergistic, and cardioprotective. Bisantrene is nestled beautifully to be that.

The shareprice most likely will not reflect value, but it will rise significantly in the eyes and minds of those paying attention.